Brief: SynAct Pharma Q4 Sales SEK 0
18/02/2025 06:30
Feb 18 (Reuters) - SynAct Pharma Q4 cash flow from operating activities SEK -17.779 million. * Q4 net income SEK -18.379 million * Q4 operating expenses SEK 20.797 million * Q4 adjusted EPS SEK -0.44
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development